Early hepatitis B viral DNA clearance predicts treatment response at week 96

Table 1 Baseline clinical data of patients before treatment

	DNA expression level at 24-wk (IU/mL)			P value
	< 10	10-103	> 103
Number of cases	54	71	47
Gender (male/female)	39/16	59/12	26/21	0.108
Age (yr)	37.79 ± 8.68	39.33 ± 6.92	35.82 ± 10.08	0.181
ALT (U/L) median (range)	333 (80-897)	367 (84-813)	319 (82-965)	0.212
AST (U/L)	206.73 ± 133.09	183 ± 147.19	177 ± 109.85	0.323
PLT (109/L)	203.02 ± 70.16	263.33 ± 96.15	176.86 ± 62.03	0.109
Total bilirubin (μmol/L)	12.19 ± 4.07	11.26 ± 6.33	9.08 ± 100.75	0.791
Albumin (g/L)	43.12 ± 8.24	45.39 ± 7.15	42.29 ± 7.29	0.838
HBV DNA (log10 IU/mL)	7.37 ± 0.49	7.59 ± 0.63	7.26 ± 0.37	0.785
HBsAg (log10 IU/mL) median (range)	3.78 (2.98-5.46)	3.66 (3.03-5.71)	3.49 (3.04-5.66)	0.801
HBeAg (s/co) median (range)	303.78 (1.32-5663.42)	179.79 (1.92-6558.76)	230.32 (1.65-6288.83)	0.206

Table 2 Rates of alanine aminotransaminase normalization according to 24-wk DNA load

	DNA expression level at 24-wk (IU/mL)
	< 10	10-103	> 103
24 wk	94.40%	85.9%	40.4%
96 wk	100%	93.0%	51.1%

ALT: Alanine aminotransaminase.

Table 3 DNA expression at 24 wk and DNA response at 96 wk

24-wk DNA (IU/mL)	DNA response at 96 wk (IU/mL)
	< 10	10-103	DNA complete response rate	No response (> 103)
< 10	90.74% (50/54)	9.26% (5/54)	100.00%	0
10-103	64.79% (46/71)	21.13% (15/71)	85.92%	14.08% (10/71)
> 103	4.26% (2/47)	27.66% (13/47)	31.92%	68.08% (32/47)

Table 4 DNA expression at 24 wk and HBeAg response at 96 wk

HBeAg response at 96 wk	DNA expression level at 24 wk (IU/mL)			P value
	< 10	10-103	> 103
Rate of conversion to HBeAg negative status	53.70% (29/54)	35.21% (25/71)	6.38% (3/47)	0.012
HBeAg conversion rate	51.85% (28/54)	32.39% (23/71)	6.38% (3/47)	0.017

Table 5 Treatment efficacies of various antiviral therapies

Virological parameter at 96 wk	LAM + ADV	Telbivudine	Entecavir tablets	Entecavir dispersible tablets	P value
HBV DNA below detection (< 1000 IU/mL as a reference)	68.75%	66.67%	79.66%	78.13%	0.089
ALT normalization rate	81.25%	75.76%	86.44%	85.94%	0.096
Rate of conversion to HBeAg negative status	31.25%	36.36%	35.59%	34.38%	0.615
HBeAg seroconversion rate	25.00%	33.33%	32.20%	31.25%	0.203

LAM: Lamivudine; AVD: Adefovir; ALT: Alanine aminotransferase.

Table 6 Predictive value of DNA load for treatment response at 96 wk in the three different groups (according to DNA load at 24 wk)

Group	AUC	95%CI	Sensitivity	Specificity	PPV	NPV
< 10 IU/mL	0.869	0.778-0.960	84.76%	87.30%	74.09%	93.04%
< 1000 IU/mL	0.797	0.684-0.883	72.00%	82.78%	64.18%	87.34%
> 1000 IU/mL	0.505	0.344-0.656	66.67%	45.45%	34.37%	76.09%

Table 7 Drug-resistant mutations in 26 cases of chronic hepatitis B virus infection

Number of cases	Resistance mutation
1	rtM204I/V + rtN236T + rtS202G
1	rtL180M + rtS202G + rtM204I/V + rtN236T
1	rtM204I/V + rtN236T
1	rtAl81V + rtM204I/V + rtN236T
1	rtM204I/V
1	rtAl81V + rtN236T + rtS202G
1	rtAl81V + rtM204I/V
1	rtL180M + rtAl81V + rtM204I/V + rtN236T
1	rtAl81V + rtM204I/V + rtS202G
1	rtAl81V + rtM204I/V + rtN236T
1	rtL180M + rtM204V
2	rtM204I + rtN236T
2	rtL180M + rtAl81V + rtM204I/V + rtN236T + rtS202G
3	rtM204I + rtN236T
4	rtN236T
4	rtAl81V + rtM204I/V + rtN236T + rtS202G